Lung Cancer Clinical Trials in Philadelphia

Showing 181-200 of 363 trials

Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC

NCT05583188

A prospective, single-arm, non-randomized, multi-center, open-label study following patients with resectable stage IIB to IIIA non-small cell lung cancer after Pulsed Electric Fields (PEF) ablation who may be candidates for standard of care neoadjuvant use of checkpoint inhibitor (nivolumab) treatment plus platinum doublet chemotherapy.

NSCLC

Galvanize Therapeutics, Inc.5 participantsStarted Feb 2023

Rochester, Minnesota, United States • Philadelphia, Pennsylvania, United States • Philadelphia, Pennsylvania, United States

TERMINATEDPHASE1/PHASE2< 1 mile

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

NCT04161391

A phase 1/2, first-in-human, open-label study to determine the safety, tolerability, PK, and preliminary efficacy of the novel RET/SRC inhibitor TPX-0046 in adult subjects with advanced or metastatic solid tumors harboring RET mutations or alterations. The study consists of three portions: 1) Phase 1 Dose Escalation and Food Effect Sub-study, and 2) Phase 1 dose expansion and 3) Phase 2 efficacy evaluation.

Non Small Cell Lung CancerMedullary Thyroid CancerRET Gene Mutation+2 more

Turning Point Therapeutics, Inc.41 participantsStarted Dec 2019

La Jolla, California, United States • Orange, California, United States • Aurora, Colorado, United States +18 more locations

Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

Lung Cancer Trials in Other Cities

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

Study of the CD40 Agonistic Monoclonal Antibody APX005M

Risk Communication in African American Smokers

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer

Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

Lung EpiCheck Biomarkers Development Study

Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer

Other Conditions in Philadelphia